 |
|
Molecular Findings in Familial Parkinson Disease in Spain
Janet Hoenicka, PhD;
Lídice Vidal, BS;
Blas Morales, MD, PhD;
Israel Ampuero, BS;
F. Javier Jiménez-Jiménez, MD, PhD;
Jose Berciano, MD, PhD;
Teodoro del Ser, MD, PhD;
Adriano Jiménez, MD, PhD;
Pedro G. Ruíz, MD, PhD;
Justo G. de Yébenes, MD, PhD
Arch Neurol. 2002;59:966-970.
Background Several genetic errors in  -synuclein (Park1) and ubiquitin carboxyl-terminal–hydrolase L1(Park5) genes cause autosomal dominant familial Parkinson disease. Mutations
in the parkin gene (Park2) are the major cause of
autosomal recessive Parkinson disease.
Objective To analyze the clinical and molecular data of 19 Spanish kindreds (13
with recessive, 4 with dominant, and 2 with uncertain inheritance) who have
familial Parkinson disease.
Methods We searched for the previously described mutations in Park1 and Park5 genes and for new or described
mutations in Park2. We used single-strand conformation
polymorphism, direct sequencing, and restriction digestion of polymerase chain
reaction (PCR)–amplified genomic DNA for this study.
Results None of these families have either Park1 or Park5 mutations. We found 5 different mutations in Park2 gene in 5 of the families with recessive inheritance.
To our knowledge, 2 of these mutations, V56E and C212Y, have not been previously
reported. The other mutations found (deletion of exons 3 and 5 and 225delA)
have been described in other ethnic groups. Heterozygous carriers of a single Park2 mutation either were asymptomatic or developed clinical
symptoms in late adulthood or after brief exposure to haloperidol therapy.
Conclusions Mutations in Park2 gene account for 38% of
the families with recessive parkinsonism in Spain. We found 2 cases of simple
heterozygous Park2 mutation carriers that developed
clinical symptoms, either in late adulthood or after brief exposure to parkinsonizing
agents. Thus, hereditary Parkinson disease has more variable clinical phenotype
and molecular defects than previously thought since heterozygous mutations
could be a risk factor for parkinsonism.
From the Unidad de Diagnóstico Molecular, Banco de Tejidos para
Investigaciones Neurológicas, Madrid (Drs Hoenicka and de Yébenes,
Ms Vidal, and Mr Ampuero), Servicios de Neurología, Hospital Universitario
S Cecilio, Granada (Dr Morales), Hospital Príncipe de Asturias, Alcalá
de Henares (Dr Jiménez-Jiménez), Hospital Severo Ochoa, Leganés
(Dr del Ser), Hospital Ramón y Cajal, Madrid, and Hospital Marqués
de Valdecilla, Cantabria (Dr Jiménez), and Fundación Jiménez
Díaz, Madrid (Drs Berciano, Ruíz, and de Yébenes), Spain.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(6):1048-1050.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Suppression of Parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein
Menendez et al.
Hum Mol Genet 2006;15:2045-2058.
ABSTRACT
| FULL TEXT
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa
Ibanez et al.
Brain 2006;129:686-694.
ABSTRACT
| FULL TEXT
Juvenile Parkinson Disease and the C212Y Mutation of Parkin
Ruiz-Linares
Arch Neurol 2004;61:444-444.
FULL TEXT
Juvenile Parkinson Disease and the C212Y Mutation of Parkin--Reply
Hoenicka
Arch Neurol 2004;61:444-444.
FULL TEXT
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse
Itier et al.
Hum Mol Genet 2003;12:2277-2291.
ABSTRACT
| FULL TEXT
|
